NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) reported new preclinical tissue-analysis data supporting the potential neuroprotective effect of its lead candidate, ExoPTEN, in an animal model of acute spinal cord injury. The results provide biological evidence for the functional recovery previously observed in treated animals.

Preclinical Tissue Analysis

The company evaluated spinal cord tissue from animals treated with ExoPTEN two months after injury. Researchers assessed biological markers associated with neurons and supporting structures across three areas: the injury site itself, and regions rostral and caudal to the injury.

Key findings include:

• Significantly higher numbers of cells positive for Myelin Basic Protein (MBP) in ExoPTEN-treated animals compared to controls.
• MBP is a key component of the protective coating surrounding nerve fibers.
• Differences were statistically significant in both the rostral region (p=0.01) and caudal region (p=0.04).

The analysis also examined NeuN, a marker for neuronal nuclei, and NF200, a marker for neuronal axons.

What the Numbers Show

The statistical significance of the MBP marker increase in both regions flanking the injury site suggests a localized preservation of neural insulation. This tissue-level finding aligns with the company's earlier report of improved functional recovery, offering a potential mechanistic explanation for the observed efficacy.

Investor Awareness Engagement

NurExone entered into an advertising and investor awareness agreement with bullVestor Medien GmbH. The agreement commences on August 10, 2026, and runs on a flexible month-to-month basis.

The engagement is subject to acceptance by the TSX Venture Exchange. No optional campaigns will commence without written approval from the company and required TSXV acceptance.

About ExoPTEN

ExoPTEN is an exosome-based therapeutic candidate using bone marrow-derived naïve exosomes loaded with proprietary siRNA targeting PTEN. It is being developed as a minimally invasive approach for recovery following nerve injury.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) has signed a binding memorandum of understanding (MOU) with Made Scientific, Inc. to establish an exclusive partnership for Good Manufacturing Practice (GMP) manufacturing and commercial supply of exosome-based therapeutics in the United States.

The collaboration leverages Made Scientific’s 60,000-square-foot FDA and EU GMP Annex 1 compliant facility in Princeton, New Jersey. NurExone intends to begin technology transfer immediately, targeting the initiation of first GMP exosome batches in the first half of 2027. This move supports the company’s lead candidate, ExoPTEN, and its broader strategy to build scalable US manufacturing infrastructure.

Partnership Structure and Terms

Under the binding MOU, Made Scientific will serve as NurExone’s exclusive US partner for manufacturing and aseptic fill-finish of bone marrow-derived exosomes. The proposed definitive agreement contemplates an initial term of five years, with options for successive five-year renewals.

The MOU includes a strict timeline: if a definitive agreement is not executed within six months of the MOU signing, the exclusivity grants and ongoing obligations will automatically terminate, subject to specified surviving obligations. This structure places immediate pressure on both parties to finalize due diligence and technical scope of work approvals.

Strategic Pivot from BioXtek

Concurrently, NurExone announced it has mutually agreed with Florida-based BioXtek Inc. not to proceed with a non-binding Letter of Intent (LOI) previously announced on April 7, 2026. This decision reflects a strategic consolidation of US GMP exosome manufacturing infrastructure under the new Made Scientific partnership. NurExone and BioXtek intend to explore potential collaborative business opportunities outside of direct production in the near future.

What the Numbers Show

The six-month deadline for executing a definitive agreement introduces significant operational urgency. While the MOU is binding regarding exclusivity during this negotiation window, the automatic termination clause means NurExone’s entire US manufacturing roadmap hinges on closing the final contract by early 2027. The shift from BioXtek to Made Scientific centralizes US operations, reducing partner dependency but increasing reliance on Made Scientific’s capacity at its Princeton facility.

Management Commentary

Dr. Lior Shaltiel, Chief Executive Officer of NurExone, stated that partnering with specialized organizations allows the company to focus on creating shareholder value while accelerating its therapeutic pipeline. Syed T. Husain, Chairman and CEO of Made Scientific, noted that the collaboration combines NurExone’s differentiated exosome platform with Made Scientific’s regulatory expertise to create an integrated pathway from development through commercial supply.